Study to Assess the Safety, Tolerability and PK/PD After 4 Weekly SC Injections of PB1046 in Subjects With Stable HFrEF

Randomized, Double-blind, Placebo-controlled, Multiple-Dose, Study to Assess the Safety, Tolerability, PK and PD After 4 Weeks of Once Weekly Sc. Inj. of PB1046 in Adults With Stable HFrEF, and in Subjects With Cardiac Dysfunction Secondary to DMD

This study will be a sequential multiple-dose escalation study that will enroll (randomize and dose) approximately 28 subjects in four cohorts consisting of 3 active and 1 placebo in Cohort 1 and 6 active and 2 placebo in subsequent cohorts. Randomized subjects will receive a fixed weekly dose of study drug or placebo for a 4 week dosing period.

Study Overview

• Status: Completed
• Conditions: Heart Failure
• Intervention / Treatment: Drug: PB1046 Injection; Drug: Placebo Injection

Detailed Description

Qualifying subjects will have a diagnosis of NYHA Class II or III heart failure with a reduced ejection fraction (HFrEF), be in stable condition, and be taking clinician-directed appropriate pharmacological therapy (e.g., angiotensin converting enzyme inhibitors, angiotensin receptor blockers or an evidence based beta blocker) for heart failure at stable doses (with the exception of diuretics) for at least 1 month prior to screening.

During the period between screening and randomization (planned first dose), the study subject will remain on stable pharmacological therapy for heart failure. Also the study subject will be in stable health with no hospitalizations or clinically significant acute illnesses between screening and randomization that would put the subject at increased risk for study participation.

Randomized subjects will receive a fixed weekly dose of study drug or placebo for a 4 week dosing period. Dose escalation in subsequent cohorts will continue if the safety and pharmacokinetic profile are deemed acceptable as assessed by the Study Review Committee.

• Study Type: Interventional
• Enrollment (Actual): 29
• Phase: Phase 2

Contacts and Locations

Study Locations

• United States
  • Alabama
    • Anniston, Alabama, United States, 36207
      • Pinnacle Research Group, LLC
  • Arizona
    • Peoria, Arizona, United States, 85381
      • Phoenix Medical Research
  • Florida
    • Daytona Beach, Florida, United States, 32117
      • Cardiology Associates Research Company
    • Miami, Florida, United States, 33173
      • Revivial Research
  • Texas
    • McKinney, Texas, United States, 75069
      • North Dallas Research Associates

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Willing and able to sign a written informed consent and follow all study-related procedures,
• Male subjects and female subjects of reproductive or childbearing potential must practice effective contraception during the study and be willing and able to continue contraception for 30 days after their last dose of study drug,
• Body mass index ≥ 18 kg/m2 and ≤ 45 kg/m2,
• Receipt of stable pharmacological therapy(ies) for heart failure for a minimum of 1 month prior to screening and between screening and randomization and are in stable clinical condition,
• NYHA Class II or III heart failure diagnosis (ischemic or non-ischemic confirmed by medical history) at least 6 months prior to screening,
• Stable HF defined as no hospitalizations for cardiac related issues within the previous 3 months prior to the screening visit or between screening and randomization,
• A screening or historical Left Ventricular Ejection Fraction ≤ 40% by centralized reading of 2-D echocardiography,
• Screening hemoglobin ≥ 9.0 g/dL secondary to the volume of blood to be collected during the study period,
• Willing and able to return to the study unit for specified study visits, and be able to self-monitor blood pressure while at home,
• Live and work in an area with reliable cellular services (e.g., Sprint®) for real time transmission of telemetry data to the core laboratory.

Exclusion Criteria:

• Have previously received PB1046 or have a known allergy to the study drug or any of its components,
• Participating in any other study and have received any other investigational medication or device within 30 days prior to screening or are taking part in a non-medication study which, in the opinion of the Investigator, would interfere with study compliance or outcome assessments,
• Diagnosed with acute coronary syndrome (ACS) or an acute myocardial infarction (MI) within 3 months of screening,
• Canadian Cardiovascular Society (CCS) Class III or IV angina necessitating frequent use of as needed short acting nitroglycerin,
• Cardiac surgery or valvuloplasty within 3 months prior to screening,
• Cerebrovascular accident or transient ischemic attack within 3 months prior to screening,
• Sustained systolic blood pressure (SBP) < 110 mmHg and/or diastolic blood pressure (DBP) < 50 mmHg (confirmed by a duplicate seated reading) on at least 3 consecutive readings (self-monitored or office) prior to randomization or overt symptomatic hypotension,
• Sustained resting heart rate >100 beats per minute (BPM) at screening (V1) or prior to randomization,
• History or evidence of clinically significant arrhythmias (uncontrolled by drug therapy or use of an implantable defibrillator), long QT syndrome or evidence of QT prolongation demonstrating QTcF > 460 ms prior to randomization (Subjects with QTcF >460 ms due to electronic pacing by an implanted pacemaker/ICD device may be enrolled),
• Clinically significant renal dysfunction as measured by the estimated glomerular filtration rate (eGFR) of < 40 mL/min/1.73m2 as calculated by the CKD-EPI creatinine-cystatin C equation at screening, or a clinically significant change in renal function between screening and baseline,
• Clinically significant liver dysfunction as measured by: alanine aminotransferase >3.0 × the upper limit of normal (ULN), aspartate aminotransferase >3.0 × the ULN, or serum bilirubin ≥ 1.6 mg/dL at screening, or a clinically significant change in liver function between screening and baseline,
• Pregnant or lactating female subjects,
• Known history of or active alcohol abuse or use of illicit drugs within 1 year prior to randomization,
• Positive screening for human immunodeficiency virus antibodies, hepatitis B surface antigen, or hepatitis C virus antibodies,
• Any major surgical procedure within 1 month prior to screening or planned surgical procedure during the study period,
• Other medical or psychiatric condition which, in the opinion of the Investigator, would place the subject at increased risk or would preclude obtaining voluntary consent/assent or would confound the secondary objectives of study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Sequential Assignment
• Masking: Quadruple

Number of Arms

5

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: PB1046 Injection, 0.2 mg/kg; Four weekly doses of PB1046 Injection, 0.2 mg/kg	Drug: PB1046 Injection; Four weekly subcutaneous injections of PB1046.; Other Names: PB1046
Experimental: PB1046 Injection, 0.4 mg/kg; Four weekly doses of PB1046 Injection, 0.4 mg/kg	Drug: PB1046 Injection; Four weekly subcutaneous injections of PB1046.; Other Names: PB1046
Experimental: PB1046 Injection, 0.6 mg/kg; Four weekly doses of PB1046 Injection, 0.6 mg/kg	Drug: PB1046 Injection; Four weekly subcutaneous injections of PB1046.; Other Names: PB1046
Experimental: PB1046 Injection, 1.2 mg/kg; Four weekly doses of PB1046 Injection, 1.2 mg/kg	Drug: PB1046 Injection; Four weekly subcutaneous injections of PB1046.; Other Names: PB1046
Placebo Comparator: Placebo Comparator; Four weekly doses of Placebo (0.9% NaCl) Injection	Drug: Placebo Injection; Four weekly subcutaneous injections of placebo.; Other Names: Placebo

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Telemetry	Number of participants with rhythm abnormalities as assessed by continuous mobile telemetry monitoring.	Up to six weeks starting 7 to 10 days before first dose.
12-Lead ECG Assessment - Incidence of Clinically Significant Findings	Number of participants with a clinically significant change from baseline in 12-Lead ECG and presence of rhythm abnormalities and relationship to exposure of PB1046 compared to placebo	Seven weeks starting the first week of dosing.
12-Lead ECG - Categorical Analysis of QT/QTc Interval - Participants With Clinically Significant Findings	Number of participants with a clinically significant change from baseline in 12-Lead ECG and presence or absence of rhythm abnormalities and relationship to exposure of PB1046 compared to placebo	Seven weeks starting the first week of dosing.
Laboratory Parameters - Serum Chemistry - Participants With Clinically Significant Findings	Number of participants with clinically significant changes from baseline in laboratory parameters (serum chemistry) and the relationship to PB1046 compared to placebo	Eight weeks starting one week before first dose.
Laboratory Parameters - Hematology - Participants With Clinically Significant Findings	Number of participants with clinically significant changes from baseline in laboratory parameters (hematology) and the relationship to PB1046 compared to placebo	Eight weeks starting one week before first dose.
Laboratory Parameters - Urinalysis - Participants With Clinically Significant Findings	Number of participants with clinically significant changes from baseline in laboratory parameters (urinalysis) and the relationship to PB1046 compared to placebo	Eight weeks starting one week before first dose.
Laboratory Parameters - eGFR	Changes from baseline in laboratory parameters (eGFR) and the relationship to PB1046 compared to placebo. Calculated using Chronic Kidney Disease Epidemiology Collaboration Equation (CKD-EPI)	Baseline, Week 2, 3, 4, 5 and 8.
Laboratory Parameters - Lipid Profile - Participants With Clinically Significant Findings	Number of participants with clinically significant changes from baseline in laboratory parameters (lipid profile) and the relationship to PB1046 compared to placebo	Eight weeks starting one week before first dose (Baseline and at Week 8).
Vital Signs - Systolic Blood Pressure	Changes from baseline in vital signs (systolic blood pressure) and the relationship to PB1046 compared to placebo.	Baseline, Day 0, Day 1, 2, 3, 5, 7, 14, 21, 22, 23, 24, 26, 28, 29, 30, 31, and 49.
Vital Signs - Heart Rate	Changes from baseline in vital signs (heart rate) and the relationship to PB1046 compared to placebo.	Baseline, Day 0, Day 1, 2, 3, 5, 7, 14, 21, 22, 23, 24, 26, 28, 29, 30, 31, and 49.
Vital Signs - Temperature	Changes from baseline in vital signs (temperature) and the relationship to PB1046 compared to placebo.	Baseline, Day 0, Day 1, 2, 3, 5, 7, 14, 21, 22, 23, 24, 26, 28, 29, 30, 31, and 49.
Vital Signs - Respiratory Rate	Changes from baseline in vital signs (respiratory rate) and the relationship to PB1046 compared to placebo.	Baseline, Day 0, Day 1, 2, 3, 5, 7, 14, 21, 22, 23, 24, 26, 28, 29, 30, 31, and 49.
Vital Signs - Diastolic Blood Pressure	Changes from baseline in vital signs (systolic blood pressure) and the relationship to PB1046 compared to placebo.	Baseline, Day 0, Day 1, 2, 3, 5, 7, 14, 21, 22, 23, 24, 26, 28, 29, 30, 31, and 49.

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Pharmacokinetic Profile - Area Under the Curve Over the Dosing Interval [AUC(0-t)]	Comparison of dose exposures [AUC(0-t)] during once weekly administration of various doses of PB1046	Pre-dose, Day 1 post-dose (1, 3, 24, 48, 72, 120 hours post-dose 1), Day 7, 14, 21 (1, 3, 24, 48, 72, 120 hours post-dose 4), Day 22, 23, 24, 26, 28, 29, 30, and 31.
Pharmacokinetic Profile - Maximum Serum Concentration (Cmax)	Comparison of dose exposures (Cmax) during once weekly administration of various doses of PB1046	Pre-dose, Day 1 post-dose (1, 3, 24, 48, 72, 120 hours post-dose 1), Day 7, 14, 21 (1, 3, 24, 48, 72, 120 hours post-dose 4), Day 22, 23, 24, 26, 28, 29, 30, and 31.
Pharmacokinetic Profile - Time to Cmax (Tmax)	Comparison of dose exposures (Tmax) during once weekly administration of various doses of PB1046	Pre-dose, Day 1 post-dose (1, 3, 24, 48, 72, 120 hours post-dose 1), Day 7, 14, 21 (1, 3, 24, 48, 72, 120 hours post-dose 4), Day 22, 23, 24, 26, 28, 29, 30, and 31.
Pharmacokinetic Profile - Elimination Rate Constant (Lambda z)	Comparison of dose exposures (lambda z) during once weekly administration of various doses of PB1046	Pre-dose, Day 1 post-dose (1, 3, 24, 48, 72, 120 hours post-dose 1), Day 7, 14, 21 (1, 3, 24, 48, 72, 120 hours post-dose 4), Day 22, 23, 24, 26, 28, 29, 30, and 31.
Pharmacokinetic Profile - Elimination Half-life (t½)	Comparison of dose exposures (t½) during once weekly administration of various doses of PB1046	Pre-dose, Day 1 post-dose (1, 3, 24, 48, 72, 120 hours post-dose 1), Day 7, 14, 21 (1, 3, 24, 48, 72, 120 hours post-dose 4), Day 22, 23, 24, 26, 28, 29, 30, and 31.
Pharmacokinetic Profile - Clearance (CL/F), Uncorrected for Bioavailability	Comparison of dose exposures (CL/F) during once weekly administration of various doses of PB1046	Pre-dose, Day 1 post-dose (1, 3, 24, 48, 72, 120 hours post-dose 1), Day 7, 14, 21 (1, 3, 24, 48, 72, 120 hours post-dose 4), Day 22, 23, 24, 26, 28, 29, 30, and 31.
Pharmacokinetic Profile - Volume of Distribution (Vz/F), Uncorrected for Bioavailability (F)	Comparison of dose exposures (Vz/F) during once weekly administration of various doses of PB1046	Pre-dose, Day 1 post-dose (1, 3, 24, 48, 72, 120 hours post-dose 1), Day 7, 14, 21 (1, 3, 24, 48, 72, 120 hours post-dose 4), Day 22, 23, 24, 26, 28, 29, 30, and 31.
Immunogenicity	Number of participants reporting positive immunogenicity (four-fold increase of pre-dose titer)	Eleven weeks starting the first week of dosing.

Collaborators and Investigators

• Sponsor: PhaseBio Pharmaceuticals Inc.

Study record dates

Study Major Dates

• Study Start (Actual): June 1, 2016
• Primary Completion (Actual): December 6, 2017
• Study Completion (Actual): December 6, 2017

Study Registration Dates

• First Submitted: June 8, 2016
• First Submitted That Met QC Criteria: June 16, 2016
• First Posted (Estimate): June 22, 2016

Study Record Updates

• Last Update Posted (Actual): July 14, 2022
• Last Update Submitted That Met QC Criteria: June 20, 2022
• Last Verified: June 1, 2022

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Heart Diseases; Cardiovascular Diseases; Heart Failure; Vasodilator Agents; VIP-ELP fusion molecule PB1046
• Other Study ID Numbers: PB1046-PT-CL-0003-P1

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO